RUSNANO is building a plant for the production of vaccines and biologics
The Supervisory Board of RUSNANO approved the project for the production of nanovaccines and therapeutic biological products. Within the framework of the project, it is planned to create two vaccines against human and avian influenza, three biological products for the treatment of toxic conditions in oncology, activation of immunity and enhancement of the action of antibacterial and antiviral drugs, as well as lower limb ischemia and amyotrophic lateral sclerosis.
To implement the project, a joint venture is being created, the participants of which will be RUSNANO and NTfarma LLC. Coordination of scientific activities will be carried out by the State Research Institute of EM named after Gamalei RAMS. It is also attended by the Research Institute of Influenza of the Russian Academy of Medical Sciences, the Institute of Molecular Genetics of the Russian Academy of Sciences, the Scientific Center of Neurology of the Russian Academy of Medical Sciences, the Federal State University P.A. Herzen Moscow Cancer Research Institute of Roszdrav, the Russian Center of Surgery. B.V. Petrovsky Academy of Medical Sciences and other scientific institutions.
The total budget of the project is 1,547 million rubles. RUSNANO will contribute 237 million rubles to pay for a 49% share in the authorized capital of the joint venture, and will also provide a loan of 1,063 million rubles for a period of 7 years. NTfarma LLC will provide financing in the form of a contribution of 100 million rubles to the authorized capital of the joint venture, as well as intellectual property, the value of which, according to Deloitte & Touche, amounted to 147 million rubles.
The launch of the project is scheduled for the 1st quarter of 2010, reaching the design capacity is planned for the 3rd quarter of 2012.
It is planned to bring two types of vaccines and therapeutic biologics to the market. The first uses self–assembling nanoparticles - modified adenoviruses that are not able to reproduce in living cells, but deliver the target gene to them. Using this gene, cells produce the desired protein, which has a therapeutic effect or, in the case of vaccines, causes an immune response. The second type of vaccines uses synthesized nanoparticles of polysaccharides. The molecules of the target protein are fixed on them with the help of a special protein module (a carbohydrate-binding domain). The technology is focused on obtaining nanoparticles with a diameter of 50-90 nanometers. The cells responsible for the primary immune response recognize particles of exactly this size.
"Nanovaccines are more effective than classical vaccines due to the induction of not only humoral, but also cellular immune response. Nanovaccines are also more convenient, since they can be applied by instillation into the nose. The technology we offer allows us to reduce the time for obtaining vaccine strains from 60 to 28 days, which is important for the development of vaccines against pandemic strains of the influenza virus," emphasizes Boris Naroditsky, one of the authors of the project, Deputy Director of the Gamalei State Research Institute of EM for Science.
"The production of more than 10 million packages per year will be built in accordance with international GMP standards (Good Manufacturing Practice). This will allow, after the saturation of the Russian market, to enter the global market of influenza vaccines, which is about $ 3 billion and is growing by 18% per year," says Olga Shpichko, Managing Director of RUSNANO.
Portal "Eternal youth" www.vechnayamolodost.ru according to the materials of the RUSNANO press service
27.07.2009